Cardiff Oncology vs Revolution Medicines
CRDF and RVMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRDF and RVMD compare
Revolution Medicines is the larger company, worth 592 times as much as Cardiff Oncology ($41.0B against $69.2M).
Cardiff Oncology scores higher on the StockData Score (7 against 3 for Revolution Medicines), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRDF | RVMD |
|---|---|---|
| Size and price | ||
| Market cap | $69.2M | $41.0B |
| Share price | $0.890 | $191.31 |
| Change, 1 year | −60.3% | 230% |
| Change, 5 years | −84.6% | 468% |
| Beta (5Y) | 1.64 | 1.35 |
| Employees | 31 | 883 |
| StockData Score | ||
| Total score | 7 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 136× | – |
| P/B | 2.6× (better) | 15.7× |
| FCF yield | – | −3.0% |
| Growth | ||
| Revenue growth (TTM) | −7.0% | – |
| Revenue growth, 5Y average | 10.1% | – |
| Profitability | ||
| Operating margin | −8320% | – |
| Net margin | −7884% | – |
| Return on equity | −94.1% | −79.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −27.4× |
| Current ratio | 3.30 | 11.38 (better) |
| Altman Z-score | −16.02 | 12.82 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 24.2% | 105% |
| Held by insiders | 4.9% | 5.3% |
| Insider net buying, 12 months | $1.1M (better) | −$153M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 16.3% | – |
Go deeper
- CRDF stock overview
- CRDF income statement
- CRDF valuation and score
- RVMD stock overview
- RVMD income statement
- RVMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.